Biotherapeutics Discovery & Development

Transformational technologies to design, construct, and optimize biotherapeutics

Informed protein design optimizes bioactivity and molecular properties resulting in superior efficacy, pharmacokinetics, pharmacodynamics, safety, manufacturability and differentiations

Bioconjugation technologies

Nucleic acid delivery technologies

Combinatorial biologics such as bi-specific and multi-functional platforms with promising biophysical and manufacturing properties

Structure-based and computational design of therapeutics including Artificial Intelligence and Machine Learning.

Novel computational technologies to rationally design antibody, protein and peptide therapeutics that display superior pharmaceutical properties (including selectivity, half-life extension, stability, formulatability)

Technologies that enhance multi-transmembrane protein target expression/presentation for antibody generation and screening

Technologies and patient sample access for antibody discovery from human antibody responses

Targeted delivery technologies that address/overcome cell/tissue selectivity, cell membrane penetration, cross blood brain barrier

Integrated service providers to support early discovery activities for development of therapeutics

Broadly applicable platforms to enhance speed/quality of antibody generation

Novel biologics, combination therapies, and mRNA therapeutics that fit Pfizer strategies